Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective trimmed by B. Riley from $205.00 to $200.00 in a research note issued to investors on Friday morning, MarketBeat reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
ALNY has been the topic of a number of other research reports. Barclays upped their target price on shares of Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an overweight rating in a research note on Wednesday, November 8th. Credit Suisse Group set a $151.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a research note on Friday, February 9th. FBR & Co started coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, October 30th. They set a buy rating and a $150.00 price objective on the stock. BMO Capital Markets dropped their price objective on shares of Alnylam Pharmaceuticals from $165.00 to $160.00 and set an outperform rating on the stock in a research note on Friday, February 9th. Finally, Cowen reiterated an outperform rating and set a $151.00 price objective (up previously from $117.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Three analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of Buy and an average target price of $126.76.
Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $122.88 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.23 and a current ratio of 12.23. Alnylam Pharmaceuticals has a 12 month low of $45.00 and a 12 month high of $147.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10). The company had revenue of $37.90 million during the quarter, compared to analyst estimates of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The business’s revenue for the quarter was up 116.6% compared to the same quarter last year. During the same quarter last year, the company posted ($1.32) EPS. equities research analysts forecast that Alnylam Pharmaceuticals will post -6.81 EPS for the current year.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 73,415 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $130.90, for a total value of $9,610,023.50. Following the sale, the chief executive officer now owns 223,125 shares in the company, valued at $29,207,062.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Laurie Keating sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the completion of the sale, the senior vice president now owns 41,500 shares in the company, valued at approximately $5,639,435. The disclosure for this sale can be found here. Insiders sold 146,409 shares of company stock worth $19,279,377 in the last 90 days. 4.30% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the business. Bradley Foster & Sargent Inc. CT increased its stake in shares of Alnylam Pharmaceuticals by 100.1% in the third quarter. Bradley Foster & Sargent Inc. CT now owns 8,235 shares of the biopharmaceutical company’s stock valued at $968,000 after purchasing an additional 4,120 shares during the period. WINTON GROUP Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $10,633,000. First Trust Advisors LP increased its stake in shares of Alnylam Pharmaceuticals by 25.3% in the third quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock valued at $92,185,000 after purchasing an additional 158,288 shares during the period. California Public Employees Retirement System boosted its holdings in shares of Alnylam Pharmaceuticals by 5.1% in the third quarter. California Public Employees Retirement System now owns 133,206 shares of the biopharmaceutical company’s stock valued at $15,650,000 after acquiring an additional 6,506 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Alnylam Pharmaceuticals by 2.4% in the third quarter. Bank of New York Mellon Corp now owns 342,105 shares of the biopharmaceutical company’s stock valued at $40,194,000 after acquiring an additional 8,163 shares in the last quarter. Institutional investors own 88.61% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals (ALNY) PT Lowered to $200.00 at B. Riley” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://ledgergazette.com/2018/02/19/alnylam-pharmaceuticals-alny-pt-lowered-to-200-00-at-b-riley-2.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.